Biotech · Private company
Ono Pharmaceutical Co., Ltd.
Track this companyFree. Adds Ono Pharmaceutical Co., Ltd. to your Dealase workspace and tells you when its record changes.
Clinical trials2510 recruiting or active
Pipeline programs17From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline17
- RituximabPhase 3 · Relapsed/Refractory Primary Central Nervous System LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- SapablursenPhase 3 · Polycythemia VeraClinicalTrials.gov · fetched Nov 12, 2026
- TemozolomidePhase 3 · Relapsed/Refractory Primary Central Nervous System LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- TirabrutinibPhase 3 · Relapsed/Refractory Primary Central Nervous System LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- 5-FluorouracilPhase 2 · Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- BevacizumabPhase 2 · Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- LeucovorinPhase 2 · Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- ONO-2020Phase 2 · Alzheimer DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- ONO-2808Phase 2 · Multiple System Atrophy (MSA)ClinicalTrials.gov · fetched Nov 12, 2026
- ONO-4578Phase 2 · Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- Opdivo®Phase 2 · Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- OxaliplatinPhase 2 · Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- TirabrutinibPhase 2 · Refractory Primary Central Nervous System LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- ONO-4685Phase 1 · Relapsed or Refractory T Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- ONO-6414Phase 1 · Ulcerative Colitis (UC)ClinicalTrials.gov · fetched Nov 12, 2026
- ONO-7018Phase 1 · Lymphoma, Non-HodgkinClinicalTrials.gov · fetched Nov 12, 2026
- TirabrutinibPhase 1 · Primary Central Nervous System Lymphoma (PCNSL)ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials25
- A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ONO-6414 Administered Orally in Healthy Adult Participants and Patients With Active Ulcerative ColitisPHASE1 · RECRUITING · started Aug 20, 2026ClinicalTrials.gov NCT07749768 · fetched Nov 12, 2026
- IGNITE: Study of Tirabrutinib vs Rituximab and Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)PHASE3 · RECRUITING · started Jun 12, 2026ClinicalTrials.gov NCT07104032 · fetched Nov 12, 2026
- INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)PHASE3 · RECRUITING · started May 25, 2026ClinicalTrials.gov NCT07429266 · fetched Nov 12, 2026
- A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal CancerPHASE2 · RECRUITING · started Nov 18, 2025ClinicalTrials.gov NCT06948448 · fetched Nov 12, 2026
- A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy ParticipantsPHASE1 · COMPLETED · started Oct 1, 2025ClinicalTrials.gov NCT07198087 · fetched Nov 12, 2026
- A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's DiseasePHASE2 · COMPLETED · started Apr 24, 2025ClinicalTrials.gov NCT06881836 · fetched Nov 12, 2026
- A Phase 2 Study of ONO-2808 in Patients With Multiple System AtrophyPHASE2 · ACTIVE_NOT_RECRUITING · started Sep 22, 2023ClinicalTrials.gov NCT05923866 · fetched Nov 12, 2026
- A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLLPHASE1 · TERMINATED · started Feb 13, 2023ClinicalTrials.gov NCT05515406 · fetched Nov 12, 2026
- Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)PHASE2 · ACTIVE_NOT_RECRUITING · started Dec 29, 2021ClinicalTrials.gov NCT04947319 · fetched Nov 12, 2026
- Study of ONO-4685 in Patients With Relapsed or Refractory T Cell LymphomaPHASE1 · ACTIVE_NOT_RECRUITING · started Dec 10, 2021ClinicalTrials.gov NCT05079282 · fetched Nov 12, 2026
- A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal CancerPHASE3 · ACTIVE_NOT_RECRUITING · started Dec 21, 2020ClinicalTrials.gov NCT04607421 · fetched Nov 12, 2026
- A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)PHASE3 · ACTIVE_NOT_RECRUITING · started Aug 5, 2019ClinicalTrials.gov NCT04008030 · fetched Nov 12, 2026
- A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder CancerPHASE3 · COMPLETED · started Nov 6, 2018ClinicalTrials.gov NCT03661320 · fetched Nov 12, 2026
- A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or AblationPHASE3 · ACTIVE_NOT_RECRUITING · started Apr 18, 2018ClinicalTrials.gov NCT03383458 · fetched Nov 12, 2026
- A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell CarcinomaPHASE3 · COMPLETED · started Jul 23, 2017ClinicalTrials.gov NCT03141177 · fetched Nov 12, 2026
- A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus CisplatinPHASE3 · COMPLETED · started Jun 29, 2017ClinicalTrials.gov NCT03143153 · fetched Nov 12, 2026
- Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial CancerPHASE3 · COMPLETED · started Mar 24, 2017ClinicalTrials.gov NCT03036098 · fetched Nov 12, 2026
- A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)PHASE3 · COMPLETED · started Mar 4, 2017ClinicalTrials.gov NCT02998528 · fetched Nov 12, 2026
- Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction CancerPHASE3 · COMPLETED · started Oct 12, 2016ClinicalTrials.gov NCT02872116 · fetched Nov 12, 2026
- An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction CancerPHASE3 · COMPLETED · started Jul 14, 2016ClinicalTrials.gov NCT02743494 · fetched Nov 12, 2026
- An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)PHASE3 · COMPLETED · started May 9, 2016ClinicalTrials.gov NCT02667587 · fetched Nov 12, 2026
- An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the CancerPHASE3 · COMPLETED · started Mar 22, 2016ClinicalTrials.gov NCT02632409 · fetched Nov 12, 2026
- An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)PHASE3 · COMPLETED · started Aug 5, 2015ClinicalTrials.gov NCT02477826 · fetched Nov 12, 2026
- Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)PHASE3 · COMPLETED · started Oct 16, 2014ClinicalTrials.gov NCT02231749 · fetched Nov 12, 2026
- An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver CancerPHASE1_PHASE2 · COMPLETED · started Oct 30, 2012ClinicalTrials.gov NCT01658878 · fetched Nov 12, 2026